Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis

BACKGROUND AND OBJECTIVE: Inebilizumab is a humanized, affinity-optimized, afucosylated immunoglobulin (Ig)-G1κ monoclonal antibody that binds to CD19, resulting in effective depletion of peripheral B cells. It is being developed to treat various autoimmune diseases, including neuromyelitis optica s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Li, Kimko, Holly, Wang, Bing, Cimbora, Daniel, Katz, Eliezer, Rees, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891208/
https://www.ncbi.nlm.nih.gov/pubmed/34718986
http://dx.doi.org/10.1007/s40262-021-01071-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891208/
https://www.ncbi.nlm.nih.gov/pubmed/34718986
http://dx.doi.org/10.1007/s40262-021-01071-5

Ejemplares similares